Get started
Author

Shelby Barnett

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
2017 · Shelby Barnett, Kayode Ogungbenro, et al. · Clinical Pharmacology & Therapeutics · 75
PDF
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I
2018 · Shelby Barnett, Kayode Ogungbenro, et al. · Journal of Pharmacology and Experimental Therapeutics · 46
PDF
In vivoscreening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
2016 · Shaunna L. Beedie, Holly M. Rore, et al. · Oncotarget · 45
PDF
Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients
2021 · Shelby Barnett, Farina Hellmann, et al. · European Journal of Cancer · 38
PDF
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability
2020 · Hiroyuki Takita, Shelby Barnett, et al. · CPT Pharmacometrics & Systems Pharmacology · 36
PDF
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
2015 · Shaunna L. Beedie, Cody J. Peer, et al. · Molecular Cancer Therapeutics · 36
PDF
Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance
2021 · A. Laura Nijstad, Shelby Barnett, et al. · European Journal of Cancer · 29
PDF
Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
2021 · Shelby Barnett, Julie Errington, et al. · Pharmaceuticals · 27
PDF
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice
2024 · Monika Berezowska, Isaac S. Hayden, et al. · British Journal of Clinical Pharmacology · 22
A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children
2022 · A. Laura Nijstad, Wan-Yu Chu, et al. · Pharmaceutical Research · 11
PDF
Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom
2020 · Shelby Barnett, Jordon Kong, et al. · British Journal of Clinical Pharmacology · 11
PDF
Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk
2023 · David Damoiseaux, Frédéric Amant, et al. · CPT Pharmacometrics & Systems Pharmacology · 8
PDF
Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations
2022 · Shelby Barnett, Victoria Holden, et al. · Frontiers in Oncology · 6
PDF
A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
2022 · Peter F. Gallagher, Gregory Naylor, et al. · Journal of Clinical Oncology · 5
Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series
2022 · Vickyanne Carruthers, Shelby Barnett, et al. · Pediatric Blood & Cancer · 5
PDF
Generation of evidence-based carboplatin dosing guidelines for neonates and infants
2023 · Shelby Barnett, Guy Makin, et al. · British Journal of Cancer · 4
PDF
Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report
2023 · Shelby Barnett, Aye Chan Nyein, et al. · Cancer Chemotherapy and Pharmacology · 3
PDF
Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom
2024 · Gerard C. Millen, Alice Lawford, et al. · British Journal of Cancer · 2
PDF
Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
2026 · Britta Vormoor, Joshua Savage, et al. · EJC Paediatric Oncology · 1
PDF
Development and validation of an LC-MS/MS method for the quantification of novel therapeutic TT-478, a selective adenosine receptor 2B antagonist, for a phase I/II clinical trial
2025 · Daniel Whitaker, Laura Francis, et al. · Bioanalysis · 1
PDF
A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups
2024 · Ma Ida Mohmaed Ali, A. Laura Nijstad, et al. · Clinical Pharmacokinetics · 1
Spontaneous fractures during 13‐cis retinoic acid therapy for neuroblastoma
2023 · Claire Geurten, Julie Errington, et al. · Pediatric Blood & Cancer · 1
PDF
First in Human: Who and what makes a cancer phase 1 trial and why are they so important?
2021 · Gaston Welisch, Chris Twelves, et al. · RADAR (Glasgow School of Art) · 1
PDF
Development and validation of a LC-MS/MS method for the quantification of the E-type prostanoid receptor 4 antagonist HTL0039732 in human plasma, for a Phase I/IIa clinical trial
2026 · Dan Astley, Svatopluk Svetlik, et al. · Figshare
Development and validation of a LC-MS/MS method for the quantification of the E-type prostanoid receptor 4 antagonist HTL0039732 in human plasma, for a Phase I/IIa clinical trial
2026 · Dan Astley, Svatopluk Svetlik, et al. · Bioanalysis
PDF
Works count: 91
Citation count: 1,700
H-index: 27
I10-index: 47
Year
Topic
Type